Display options
Cite
Erstad DJ, Tager AM, Hoshida Y, et al. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Mol Cell Oncol. 2017;4(3):e1311827doi: 10.1080/23723556.2017.1311827.
Erstad, D. J., Tager, A. M., Hoshida, Y., & Fuchs, B. C. (2017). The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Molecular & cellular oncology, 4(3), e1311827. https://doi.org/10.1080/23723556.2017.1311827
Erstad, Derek J, et al. "The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer." Molecular & cellular oncology vol. 4,3 (2017): e1311827. doi: https://doi.org/10.1080/23723556.2017.1311827
Erstad DJ, Tager AM, Hoshida Y, Fuchs BC. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Mol Cell Oncol. 2017 Mar 31;4(3):e1311827. doi: 10.1080/23723556.2017.1311827. eCollection 2017. PMID: 28616586; PMCID: PMC5462520.
Copy Download .nbib Format: NLM
Share it on

Mol Cell Oncol. 2017 Mar 31;4(3):e1311827. doi: 10.1080/23723556.2017.1311827. eCollection 2017.

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.

Molecular & cellular oncology

Derek J Erstad, Andrew M Tager, Yujin Hoshida, Bryan C Fuchs

Affiliations

  1. Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  2. Center for Immunology and Inflammatory Diseases, Fibrosis Research Center, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  3. Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 28616586 PMCID: PMC5462520 DOI: 10.1080/23723556.2017.1311827

Abstract

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Keywords: ATX; HCC; LPA; LPAR1; NASH; chemoprevention; cirrhosis; fibrosis; hepatocellular carcinoma; non-alcoholic steatohepatitis

References

  1. Curr Cancer Drug Targets. 2012 Nov 1;12(9):1129-59 - PubMed
  2. J Hepatol. 2017 May;66(5):919-929 - PubMed
  3. J Biochem. 2015 Feb;157(2):81-9 - PubMed
  4. J Pharmacol Exp Ther. 2017 Jan;360(1):1-13 - PubMed
  5. Clin Chim Acta. 2011 Jun 11;412(13-14):1201-6 - PubMed
  6. Oncology. 2017;92 Suppl 1:50-62 - PubMed
  7. Cancer Cell. 2016 Dec 12;30(6):879-890 - PubMed
  8. Hepatology. 2014 Apr;59(4):1577-90 - PubMed
  9. Hepatology. 2017 Apr;65(4):1369-1383 - PubMed
  10. Hepatology. 2014 Nov;60(5):1767-75 - PubMed

Publication Types

Grant support